NCT02983578View on ClinicalTrials.gov

Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

March 2, 2017

Primary Completion Date

August 30, 2025

Study Completion Date

August 30, 2025

Conditions
Advanced Colorectal CarcinomaAdvanced Lung Non-Small Cell CarcinomaLung Non-Small Cell CarcinomaMismatch Repair DeficiencyRefractory Colorectal CarcinomaRefractory Lung CarcinomaRefractory Pancreatic CarcinomaStage II Pancreatic Cancer AJCC v8Stage III Colorectal Cancer AJCC v8Stage III Lung Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage IIIA Colorectal Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8Stage IIIB Colorectal Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Stage IIIC Colorectal Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8Stage IV Colorectal Cancer AJCC v8Stage IV Lung Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8Stage IVA Colorectal Cancer AJCC v8Stage IVA Lung Cancer AJCC v8Stage IVB Colorectal Cancer AJCC v8Stage IVB Lung Cancer AJCC v8Stage IVC Colorectal Cancer AJCC v8
Interventions
DRUG

Danvatirsen

Given IV

BIOLOGICAL

Durvalumab

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

AstraZeneca

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER